Results 181 to 190 of about 156,017 (326)

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair, Bernhard Hellmich, Arnaud Bourdin, David R. W. Jayne, Florence Roufosse, Nader Khalidi, Lena Börjesson Sjö, Ying Fan, Christopher McCrae, Sofia Necander, Eva Rodríguez‐Suárez, Anat Shavit, Claire Walton, Peter A. Merkel, Michael E. Wechsler   +14 more
wiley   +1 more source

30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study [PDF]

, 2019
Kimberly E. Vanover, Steven Glass, Susan G Kozauer, Jelena Saillard, Juan Manuel Sepúlveda-Sánchez, Michal Weingart, Sharon Mates, Andrew Satlin, Robert E. Davis   +8 more
openalex   +1 more source

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study [PDF]

, 2023
Masataka Kuwana, Tomoki� Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, Natsuko Shichiri, So Saotome, Esteban S. Masuda, Yoshiaki Tomiyama   +12 more
openalex   +1 more source

Do Perceptions of Ballot Secrecy Influence Turnout? Results from a Field Experiment [PDF]

Although the secret ballot has long been secured as a legal matter in the United States, formal secrecy protections are not equivalent to convincing citizens that they may vote privately and without fear of reprisal. We present survey evidence that those
Alan S. Gerber, Conor M. Dowling, David Doherty, Gregory A. Huber, Seth J. Hill   +4 more
core  

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial

, 2021
Masamitsu Hyodo, Asuka Nagao, Kento Asano, Masahiko Sakaguchi, Kenji Mizoguchi, Koichi Omori, Yasuhiro Tada, Hiromitsu Hatakeyama, Nobuhiko Oridate, Kensei Naito, Yoshihiro Iwata, Hirotaka Shinomiya, Hirotaka Hara, Tetsuji Sanuki, Eiji Yumoto   +14 more
openalex   +2 more sources

Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase [PDF]

, 2020
Masahiro Abo, Takashi Shigematsu, Hiroyoshi Hara, Yasuko Matsuda, Akinori Nimura, Yoshiyuki Yamashita, Kaoru Takahashi   +6 more
openalex   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Open-Label-Placebos zur Appetitreduktion bei Kindern mit Übergewicht und Adipositas: Eine Studie zur Wirksamkeit und eine Umfrage zur Einstellung gegenüber Open-Label-Placebos

, 2023
Übergewicht und Adipositas im Kindesalter gehen mit einer Vielzahl chronischer Erkrankungen und einer erhöhten Mortalität bereits im jungen Erwachsenenalter einher. In Österreich ist jedes vierte Kind zwischen acht und neun Jahren von Übergewicht oder Adipositas betroffen.
openaire